An FDA panel reviewing Amylyx's ALS drug was moved by patient testimony—but they voted it down anyway

An FDA advisory panel says the evidence supporting Amylyx’s amyotrophic lateral sclerosis drug, which amounted to just one study, isn't strong enough to warrant FDA approval.

The decision came down to 4 yeas and 6 nays, with no abstentions. Many of the committee members expressed how difficult the decision was, regardless of whether they fell on the yes or no side.